Olanzapine versus aripiprazole for the treatment of agitation in acutely ill patients with schizophrenia

Journal of Clinical Psychopharmacology

Volumn 28, Issue 6, 2008, Pages 601-607

  Kinon, Bruce J ^a   Stauffer, Virginia L ^a   Kollack Walker, Sara ^a   Chen, Lei ^a   Sniadecki, Jennifer ^a  

^a ELI LILLY AND COMPANY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARIPIPRAZOLE; GLUCOSE; LORAZEPAM; OLANZAPINE; PROLACTIN; TRIACYLGLYCEROL; BENZODIAZEPINE DERIVATIVE; DOPAMINE RECEPTOR BLOCKING AGENT; NEUROLEPTIC AGENT; PIPERAZINE DERIVATIVE; QUINOLONE DERIVATIVE;

ACUTE DISEASE; ADULT; AGED; AGITATION; ANXIETY; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CONVULSION; DISEASE ASSOCIATION; DISEASE EXACERBATION; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; HEADACHE; HUMAN; INSOMNIA; MAJOR CLINICAL STUDY; MALE; PNEUMONIA; POSITIVE AND NEGATIVE SYNDROME SCALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SCHIZOPHRENIA; SIDE EFFECT; ADOLESCENT; BLOOD; COMPARATIVE STUDY; DRUG EFFECT; GLUCOSE BLOOD LEVEL; HOSPITALIZATION; MIDDLE AGED; MULTICENTER STUDY; ORAL DRUG ADMINISTRATION; PSYCHOLOGICAL RATING SCALE; PSYCHOLOGY; RESTLESSNESS; TIME; TREATMENT OUTCOME; UNITED STATES;

ACUTE DISEASE; ADMINISTRATION, ORAL; ADOLESCENT; ADULT; AGED; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; BLOOD GLUCOSE; DOPAMINE ANTAGONISTS; DOUBLE-BLIND METHOD; FEMALE; HOSPITALIZATION; HUMANS; LORAZEPAM; MALE; MIDDLE AGED; PIPERAZINES; PROLACTIN; PSYCHIATRIC STATUS RATING SCALES; PSYCHOMOTOR AGITATION; QUINOLONES; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; TIME FACTORS; TREATMENT OUTCOME; TRIGLYCERIDES; UNITED STATES; YOUNG ADULT;

EID: 59049088231     PISSN: 02710749     EISSN: None     Source Type: Journal    
DOI: 10.1097/JCP.0b013e31818aaf6c     Document Type: Article

References (30)

1. Baker RW, Kinon BJ, Maguire GA, et al. Effectiveness of rapid initial dose escalation of up to forty milligrams per day of oral olanzapine in acute agitation. J Clin Psychopharmacol. 2003;23:342-348.
2. Beasley CM Jr, Sanger T, Satterlee W, et al. Olanzapine versus placebo: results of a double-blind, ?xed-dose olanzapine trial. Psychopharmacology (Berl). 1996;124:159-167.
3. Beasley CM Jr, Hamilton SH, Crawford AM, et al. Olanzapine versus haloperidol: acute phase results of the international double-blind olanzapine trial. Eur Neuropsychopharmacol. 1997;7:125-137.
4. Breier A, Meehan K, Birkett M, et al. A double-blind, placebo- controlled dose-response comparison of intramuscular olanzapine and haloperidol in the treatment of acute agitation in schizophrenia. Arch Gen Psychiatry. 2002;59:441-448.
5. Kinon BJ, Ahl J, Rotelli MD, et al. Ef?cacy of accelerated dose titration of olanzapine with adjunctive lorazepam to treat acute agitation in schizophrenia. Am J Emerg Med. 2004;22:181-186.
6. Wright P, Birkett M, David SR, et al. Double-blind, placebo-controlled comparison of intramuscular olanzapine and intramuscular haloperidol in the treatment of acute agitation in schizophrenia. Am J Psychiatry. 2001;158:1149-1151.
7. Wright P, Meehan K, Birkett M, et al. A comparison of the ef?cacy and safety of olanzapine versus haloperidol during transition from intramuscular to oral therapy. Clin Ther. 2003;25:1420-1428.
8. Wright P, Lindborg SR, Birkett M, et al. Intramuscular olanzapine and intramuscular haloperidol in acute schizophrenia: antipsychotic ef?cacy and extrapyramidal safety during the ?rst 24 hours of treatment. Can J Psychiatry. 2003;48:716-721.
9. Burris KD, Molski TF, Xu C, et al. Aripiprazole, a novel antipsychotic, is a high-af?nity partial agonist at human dopamine D2 receptors. J Pharmacol Exp Ther. 2002;302:381-389.
10. Lawler CP, Prioleau C, Lewis MM, et al. Interactions of the novel antipsychotic aripiprazole (OPC-14597) with dopamine and serotonin receptor subtypes. Neuropsychopharmacology. 1999;20:612-627.
11. Kane JM, Carson WH, Saha AR, et al. Ef?cacy and safety of aripiprazole and haloperidol versus placebo in patients with schizophrenia and schizoaffective disorder. J Clin Psychiatry. 2002;63:763-771.
12. Potkin SG, Saha AR, Kujawa MJ, et al. Aripiprazole, an antipsychotic with a novel mechanism of action, and risperidone vs placebo in patients with schizophrenia and schizoaffective disorder. Arch Gen Psychiatry. 2003;60:681-690.
13. Andrezina R, Josiassen RC, Marcus RN, et al. Intramuscular aripiprazole for the treatment of acute agitation in patients with schizophrenia or schizoaffective disorder: a double-blind, placebo-controlled comparison with intramuscular haloperidol. Psychopharmacology (Berl). 2006;188:281-292.
14. Tran-Johnson TK, Sack DA, Marcus RN, et al. Ef?cacy and safety of intramuscular aripiprazole in patients with acute agitation: a randomized, double-blind, placebo-controlled trial. J Clin Psychiatry. 2007;68: 111-119.
15. BMS. Clinical Study Report CN138-003: A multicenter, double-blind, randomized, comparative study of aripiprazole and olanzapine in the treatment of patients with acute schizophrenia. Bristol-Meyers Squibb Clinical Trial Disclosure; 2007. Available at: http://ctr.bms.com/ctd/ ResultDetailAction.do? prodid=14&trialid=763. Accessed November 26, 1007.
16. McQuade RD, Stock E, Marcus R, et al. A comparison of weight change during treatment with olanzapine or aripiprazole: results from a randomized, double-blind study. J Clin Psychiatry. 2004;65(suppl 18): 47-56.
17. Kay SR, Fiszbein A, Opler LA. The Positive and Negative Syndrome Scale (PANSS) for schizophrenia. Schizophr Bull. 1987;13:261-276.
18. Overall JE, Gorham DR. The Brief Psychiatric Rating Scale. Psychol Rep. 1962;10:799-812.
19. Battaglia J, Lindborg SR, Alaka K, et al. Calming versus sedative effects of intramuscular olanzapine in agitated patients. Am J Emerg Med. 2003;21:192-198.
20. Simpson GM, Angus JW. A rating scale for extrapyramidal side effects. Acta Psychiatr Scand Suppl. 1970;212:11-19.
21. Barnes RE. A rating scale for drug-induced Akathisia. Br J Psychiatry. 1989;154:672-676.
22. American Diabetes Association. Diagnosis and classi?cation of diabetes mellitus. Diabetes Care. 2008;31(suppl 1):S55-S60.
23. Executive Summary of the Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA. 2001;285:2486-2497.
24. Volavka J, Czobor P, Citrome L, et al. Ef?cacy of aripiprazole against hostility in schizophrenia and schizoaffective disorder: data from 5 double-blind studies. J Clin Psychiatry. 2005;66:1362-1366.
25. Marder SR, West B, Lau GS, et al. Aripiprazole effects in patients with acute schizophrenia experiencing higher or lower agitation: a post hoc analysis of 4 randomized, placebo-controlled clinical trials. J Clin Psychiatry. 2007;68:662-668.
26. Guy W. Clinical Global Impression. ECDEU Assessment Manual for Psychopharmacology, Revised. Rockville, MD: National Institute of Mental Health; 1976:24.
27. Kane JM, Osuntokun O, Kryzhanovskaya L, et al. A 28-week, randomized, double-blind study of olanzapine versus aripiprazole in the treatment of schizophrenia. Paper presented at the 161st Annual Meeting of the American Psychiatric Association; May 2008; Washington, DC.
28. Citrome L. A review of aripiprazole in the treatment of patients with schizophrenia or bipolar I disorder. Neuropsychiatr Dis Treat. 2006;2: 427-443.
29. Raja M. Improvement or worsening of psychotic symptoms after treatment with low doses of aripiprazole. Int J Neuropsychopharmacol. 2007; 10:107-110.
30. Ramaswamy S, Vijay D, et al. Aripiprazole possibly worsens psychosis. Int Clin Psychopharmacol. 2004;19:45-48.